CD274 and cancer: Since PD-1/PD-L1 blockade will increase the amplitude of therapeutic cancer vaccine-mediated activated T-cell responses in the TME, therapeutic cancer vaccines combined with PD-1/PD-L1 immune checkpoint blockade therapy could be a reasonable approach with the potential for cancer-free survival (139).